DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Opana Er is a drug marketed by Endo Pharms and is included in two NDAs. There are eleven patents protecting this drug.
This drug has two hundred and fifty-three patent family members in thirty-two countries.
The generic ingredient in OPANA ER is oxymorphone hydrochloride. There are nine drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the oxymorphone hydrochloride profile page.
A generic version of OPANA ER was approved as oxymorphone hydrochloride by IMPAX LABS on June 14th, 2010.
Summary for OPANA ER
|Raw Ingredient (Bulk) Api Vendors:||6|
|Formulation / Manufacturing:||see details|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for OPANA ER|
|What excipients (inactive ingredients) are in OPANA ER?||OPANA ER excipients list|
|DailyMed Link:||OPANA ER at DailyMed|
|Country||Patent Number||Estimated Expiration|
|China||1551770||⤷ Free Forever Trial|
|Spain||2289542||⤷ Free Forever Trial|
|Japan||4895821||⤷ Free Forever Trial|
|Greece||950300035||⤷ Free Forever Trial|
|Taiwan||200640501||⤷ Free Forever Trial|
|Finland||107231||⤷ Free Forever Trial|
|Poland||1740156||⤷ Free Forever Trial|
|>Country||>Patent Number||>Estimated Expiration|